Irreversible tyrosine kinase inhibitors of epidermal growth factor receptors family – a new, promising therapeutic strategy
Journal Title: OncoReview - Year 2012, Vol 2, Issue 1
Abstract
Inhibitors of tyrosine kinase residues of epidermal growth factor receptor family (ErbB) have became a treatment of choice in many tumor types. However, even in the presence of predictive factors some patients completely do not benefit from this kind of therapy and basically all responding patients will ultimately develop resistance. Detailed characterization of function and signaling of ErbB receptors revealed that reversible blockade of those receptors represented one of potential escape mechanisms from this particular molecular intervention. Following this observation has several companies generated a novel class of drugs – irreversible ErbB-receptors tyrosine kinase inhibitors. Preclinical and clinical research demonstrated that complete and irreversible blockade of ErbB receptors efficiently inhibited signaling pathways responsible for growth and progression of malignant process leading to objective responses in advanced cancer patients. This article aims to review promising clinical data on the use of irreversible tyrosine kinasase inhibitors in various malignancies with a special focus on lung and breast cancer.
Authors and Affiliations
Piotr Wysocki
Keywords
Related Articles
- EP ID EP53134
- DOI -
- Views 250
- Downloads 0
Advanced skin melanoma – systemic treatment
In Poland, morbidity and mortality rates for melanoma are constantly increasing. In the case of inoperable disease or distant metastases, prognosis remains poor. For many years, dacarbazine has been the gold standard in...
Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients With Metastatic Neuroendocrine Midgut Tumors: A Report From the PROMID Study Group
Purpose: Somatostatin analogs are indicated for symptom control in patients with gastroenteropancreatic neuroendocrine tumors (NETs). The ability of somatostatin analogs to control the growth of well-differentiated metas...
Adriamycin cardiomyopathy with congestive heart failure, cardiogenic shock and emergency heart transplant: 30-year follow up
Doxorubicin chemotherapeutic agent is widely utilized for many types of cancers since the late 1960s. Cardiomyopathy is a well-known side effect of doxorubicin often limiting its use. In many cases doxorubicin cardiomyop...
Cardiotoxicity in breast cancer patients after radiotherapy – modern methods of minimizing the dose to the heart and dilemmas of choosing critical cardiac structures for monitoring dose distribution
Radiotherapy in breast cancer patients is an important component of multidisciplinary treatment. It reduces the risk of local recurrence and mortality from breast cancer. However, it can lead to secondary effects due to...
Pituitary adenoma occurring with acromegaly coexisting with partially empty sella syndrome
Pituitary microadenoma occurring with acromegaly coexisting with empty sella syndrome is a rare clinical case. The main symptoms result from the presence of hormonally active pituitary tumor. Empty sella syndrome may hin...